3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
3
Terminated
1
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Prostatic Neoplasms
8
Breast Neoplasms
8
Lung Neoplasms
6
Colorectal Neoplasms
6
Stomach Neoplasms
4
Pancreatic Neoplasms
4
Neoplasm Metastasis
4
Hematologic Neoplasms
4
Anatomic Stage I Breast Cancer AJCC v8
4
Rectal Neoplasms
3
Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
COVID-19
3
Uterine Cervical Neoplasms
2
Smoking
2
Sarcoma
2
Ovarian Neoplasms
2
Multiple Myeloma
2
Lymphoma
2
Head and Neck Neoplasms
2
Head and Neck Carcinoma
2
Glioblastoma
2
Gastrointestinal Neoplasms
2
Esophageal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Hepatocellular
2
Breast Carcinoma In Situ
2
Xerostomia
1
Urologic Neoplasms
1
Urologic Diseases
1
Interventions
Dexamethasone
18
Cyclophosphamide
16
fludarabine
11
pomalidomide
9
pembrolizumab
9
carfilzomib
9
daratumumab
7
Rituximab
7
Lenalidomide
7
Calcium Dobesilate
7
fludarabine phosphate
6
Gemcitabine
6
Cisplatin
6
Bortezomib
6
venetoclax
5
elotuzumab
4
isatuximab
3
blinatumomab
3
Vincristine
3
Radiotherapy
3
Prednisone
3
Etoposide
3
Doxorubicin
3
Cytarabine
3
tisagenlecleucel
2
selinexor
2
ruxolitinib
2
ixazomib
2
dexamethasone 21-phosphate
2
cabazitaxel
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Recurrence
×
Standard of Care
×
Clear all
NCT05704829
2025-11-19
ADAPTHER2-IV
West German Study Group
Phase 2
Active not recruiting
402 enrolled